MSMichael L. Steinberg

Michael L. Steinberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael L. Steinberg has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

    by Amar U. Kishan, Yuliya Zektser, Adam E. Singer, Kekoa Taparra, Luca F. Valle, Michael L. Steinberg, Nicholas G. Nickols, Robert E. Reiter, Johannes Czernin, Jeremie Calais, et al.

    A case vignette is presented of a patient with recurrent prostate cancer after radical prostatectomy, covering the spectrum from biochemical recurrence to metastatic disease. The patient provides his insight into this journey as he is treated on serial clinical trials as the disease recurs.

  • Top Cited Papers
    Open Access

    177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

    by Amar U. Kishan, Luca F. Valle, Holly Wilhalme, Carol Felix, Rejah Nabong, Jesus E. Juarez-Casillas, Kevin Flores, T. Martin Ma, Vinicius Ludwig, Mariko Nakayama, et al.

    PURPOSE: Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)–targeting radioligand therapy to SBRT would improve outcomes. METHODS: The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177 Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959 ). RESULTS: From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177 Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177 Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177 Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177 Lu + SBRT group). Prognostic biomarkers for PFS were identified. CONCLUSION: Compared with SBRT alone, the addition of 177 Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.


  • Open Access

    Data from Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer

    by Amar U. Kishan, Kristen McGreevy, Luca Valle, Michael Steinberg, Beth Neilsen, Maria Casado, Minsong Cao, Donatello Telesca, Joanne B. Weidhaas

    Purpose:Although radiotherapy (RT) is one of the primary treatment modalities used in the treatment of cancer, patients often experience toxicity during or after treatment. RT-induced genitourinary (GU) toxicity is a significant survivorship challenge for patients with prostate cancer, but identifying those at risk has been challenging. Herein, we attempt (i) to validate a previously identified biomarker of late RT-induced GU toxicity, PROSTOX, consisting primarily of miRNA-based germline biomarkers (mirSNPs), and (ii) investigate the possibility of temporally and genetically defining other forms of RT-associated GU toxicity.Experimental Design:We included 148 patients enrolled in Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE; NCT 04384770), a trial comparing MRI- versus CT-guided prostate stereotactic body RT. Linear regression was used to evaluate the association between PROSTOX score and late GU grade toxicity. Machine learning approaches were used to develop predictive models for acute toxicity and chronic GU toxicity, and the accuracy of all models was assessed using AUC metrics. A comparative Gene Ontology analysis was performed.Results:PROSTOX accurately predicts late GU toxicity, achieving an AUC of 0.76, and demonstrates strong correlation with GU toxicity grade (p-1.2E−9). mirSNP-based signatures can distinguish acute RT-associated GU toxicity and chronic RT-associated GU toxicity (AUCs of 0.770 and 0.763, respectively). Finally, Gene Ontology analysis identifies unique pathways involved in each form of GU toxicity: acute, chronic, and late.Conclusions:These findings provide strong evidence for the continued application of mirSNPs to predict toxicity to RT and act as a path for the continued personalization of RT with improved patient outcomes.

  • Open Access

    Supplemental Tables 1-12 from Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer

    by Amar U. Kishan, Kristen McGreevy, Luca Valle, Michael Steinberg, Beth Neilsen, Maria Casado, Minsong Cao, Donatello Telesca, Joanne B. Weidhaas

    Supplemental Tables 1-12 from Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer

  • Open Access

    Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer

    by Amar U. Kishan, Kristen McGreevy, Luca Valle, Michael Steinberg, Beth Neilsen, Maria Casado, Minsong Cao, Donatello Telesca, Joanne B. Weidhaas

    Purpose: Although radiotherapy (RT) is one of the primary treatment modalities used in the treatment of cancer, patients often experience toxicity during or after treatment. RT-induced genitourinary (GU) toxicity is a significant survivorship challenge for patients with prostate cancer, but identifying those at risk has been challenging. Herein, we attempt (i) to validate a previously identified biomarker of late RT-induced GU toxicity, PROSTOX, consisting primarily of miRNA-based germline biomarkers (mirSNPs), and (ii) investigate the possibility of temporally and genetically defining other forms of RT-associated GU toxicity. Experimental Design: We included 148 patients enrolled in Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE; NCT 04384770), a trial comparing MRI- versus CT-guided prostate stereotactic body RT. Linear regression was used to evaluate the association between PROSTOX score and late GU grade toxicity. Machine learning approaches were used to develop predictive models for acute toxicity and chronic GU toxicity, and the accuracy of all models was assessed using AUC metrics. A comparative Gene Ontology analysis was performed. Results: PROSTOX accurately predicts late GU toxicity, achieving an AUC of 0.76, and demonstrates strong correlation with GU toxicity grade (p-1.2E−9). mirSNP-based signatures can distinguish acute RT-associated GU toxicity and chronic RT-associated GU toxicity (AUCs of 0.770 and 0.763, respectively). Finally, Gene Ontology analysis identifies unique pathways involved in each form of GU toxicity: acute, chronic, and late. Conclusions: These findings provide strong evidence for the continued application of mirSNPs to predict toxicity to RT and act as a path for the continued personalization of RT with improved patient outcomes.


  • Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study

    by John Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, Andres Ricaurte-Fajardo, Eric Li, James A. Proudfoot, Elai Davicioni, Ariel E. Marciscano, Joseph R. Osborne, Christopher E. Barbieri, et al.

    PURPOSE: To characterize the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)–based metastatic spread. MATERIALS AND METHODS: We identified patients from four institutions who underwent PSMA PET/CT scans pretreatment for primary staging or postradical prostatectomy (RP) for suspected recurrence and had Decipher transcriptomic data available from biopsy or RP specimens. PSMA PET/CT-based patterns of spread were classified as localized (miT + N0M0) or nonlocalized (miN1M0 or miM1a-c). We calculated the association between Decipher scores and the risk of nonlocalized disease on PSMA PET/CT using multivariable logistic regression for pretreatment patients and multivariable Cox regression for post-RP patients. We also compared select transcriptomic signatures between patients with localized and nonlocalized diseases. RESULTS: Five hundred eighty-six patients were included (pretreatment: n = 329; post-RP: n = 257). Higher Decipher scores were associated with nonlocalized disease on PSMA PET/CT both pretreatment (odds ratio, 1.18 [95% CI, 1.03 to 1.36] per 0.1 increase in Decipher score, P = .02) and post-RP (hazard ratio, 1.15 [95% CI, 1.05 to 1.27] per 0.1 increase in Decipher score, P = .003). In the pretreatment setting, nonlocalized disease was associated with higher rates of TP53 mutations and lower rates of PAM50 luminal A subtype compared with localized disease. In the post-RP setting, overexpression of signatures related to metabolism, DNA repair, and androgen receptor signaling were associated with higher rates of nonlocalized disease. CONCLUSION: Higher Decipher scores were associated with nonlocalized disease identified on PSMA PET/CT both pretreatment and post-RP. There were several transcriptomic differences between localized and nonlocalized diseases in both settings.


  • Open Access

    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate

    by Soumyajit Roy, Tahmineh Romero, Jeff M. Michalski, Felix Y. Feng, Jason A. Efstathiou, Colleen A.F. Lawton, Michel Bolla, Philippe Maingon, Theo de Reijke, David Joseph, et al.

    PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS: Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendall's tau and the R2). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS: Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendall's tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION: BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.


  • Open Access

    Supplementary Figure S3 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma

    by Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D. Nelson, Sarah M. Dry, Jackie Hernandez, et al.

    Figure S3 - Distribution of soft tissue sarcoma histologic subtypes among patients enrolled on the five-day neoadjuvant RT phase 2 study

  • Open Access

    Supplementary Figure S4 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma

    by Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D. Nelson, Sarah M. Dry, Jackie Hernandez, et al.

    Figure S4 - Characteristics of major wound complications.

  • Open Access

    Supplementary Tables S1-S5 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma

    by Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D. Nelson, Sarah M. Dry, Jackie Hernandez, et al.